<DOC>
	<DOCNO>NCT01990859</DOCNO>
	<brief_summary>The purpose study assess safety Ipilimumab monotherapy Japanese subject advance melanoma</brief_summary>
	<brief_title>Phase 2 Study Ipilimumab Japanese Advanced Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Histologically cytologically confirm diagnosis malignant melanoma Previouslytreated untreated unresectable Stage III Stage IV melanoma Measurable/evaluable disease per modify World Health Organization ( mWHO ) criterion , within 28 day first dose study drug Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Active brain metastasis Primary ocular mucosal melanoma History current active autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>